Efficacy and safety outcomes among treatment-experienced women and men treated with etravirine in gender, race and clinical experience

Sally Hodder, Dushyantha T Jayaweera, Joseph Mrus, Robert Ryan, James Witek

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The GRACE (Gender, Race and Clinical Experience) trial enrolled treatment-experienced, HIV-1-infected patients, mainly women, in North America, to assess outcomes with a darunavir/ritonavir-based regimen, which could include etravirine (ETR). We present outcomes at week 48 for men and women receiving ETR. Virologic response (HIV-1 RNA <50 copies/ml) and safety were assessed; descriptive statistics are reported. To evaluate the independent contribution of ETR treatment, a post hoc analysis including a multivariate model assessed factors predictive of virologic response for the entire GRACE population (429 patients). Of 207 patients who received ETR (women, 57.5%; black or Hispanic, 81.7%), 71.4% of women and 79.5% of men completed the study. Week 48 virologic response rates in women and men (intent-to-treat population) were 58.0% and 61.4%, respectively. After censoring patients who discontinued treatment for reasons other than virologic failure, response rates were 79.3% and 73.0%, respectively. Overall, ETR was well tolerated. Women experienced more nausea (24.4% vs. 11.4%) and rash-related events (21.0% vs. 15.9%), but less diarrhea (15.1% vs. 21.6%), compared with men. Grade 3-4 hypertriglyceridemia was more common in men (9.3%) than women (1.1%). In total, 11 (9.2%) women and 7 (8.0%) men discontinued ETR due to adverse events. In the multivariate model of the entire GRACE population, ETR use was independently associated with improved virologic response. ETR is effective and well tolerated in treatment-experienced patients with HIV-1, with similar outcomes among women and men.

Original languageEnglish
Pages (from-to)544-551
Number of pages8
JournalAIDS Research and Human Retroviruses
Volume28
Issue number6
DOIs
StatePublished - Jun 1 2012

Fingerprint

etravirine
Safety
HIV-1
Population
Ritonavir
Hypertriglyceridemia
Therapeutics
North America
Exanthema

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

Efficacy and safety outcomes among treatment-experienced women and men treated with etravirine in gender, race and clinical experience. / Hodder, Sally; Jayaweera, Dushyantha T; Mrus, Joseph; Ryan, Robert; Witek, James.

In: AIDS Research and Human Retroviruses, Vol. 28, No. 6, 01.06.2012, p. 544-551.

Research output: Contribution to journalArticle

@article{34a25524e5354c14a59d5bc1fb82b1af,
title = "Efficacy and safety outcomes among treatment-experienced women and men treated with etravirine in gender, race and clinical experience",
abstract = "The GRACE (Gender, Race and Clinical Experience) trial enrolled treatment-experienced, HIV-1-infected patients, mainly women, in North America, to assess outcomes with a darunavir/ritonavir-based regimen, which could include etravirine (ETR). We present outcomes at week 48 for men and women receiving ETR. Virologic response (HIV-1 RNA <50 copies/ml) and safety were assessed; descriptive statistics are reported. To evaluate the independent contribution of ETR treatment, a post hoc analysis including a multivariate model assessed factors predictive of virologic response for the entire GRACE population (429 patients). Of 207 patients who received ETR (women, 57.5{\%}; black or Hispanic, 81.7{\%}), 71.4{\%} of women and 79.5{\%} of men completed the study. Week 48 virologic response rates in women and men (intent-to-treat population) were 58.0{\%} and 61.4{\%}, respectively. After censoring patients who discontinued treatment for reasons other than virologic failure, response rates were 79.3{\%} and 73.0{\%}, respectively. Overall, ETR was well tolerated. Women experienced more nausea (24.4{\%} vs. 11.4{\%}) and rash-related events (21.0{\%} vs. 15.9{\%}), but less diarrhea (15.1{\%} vs. 21.6{\%}), compared with men. Grade 3-4 hypertriglyceridemia was more common in men (9.3{\%}) than women (1.1{\%}). In total, 11 (9.2{\%}) women and 7 (8.0{\%}) men discontinued ETR due to adverse events. In the multivariate model of the entire GRACE population, ETR use was independently associated with improved virologic response. ETR is effective and well tolerated in treatment-experienced patients with HIV-1, with similar outcomes among women and men.",
author = "Sally Hodder and Jayaweera, {Dushyantha T} and Joseph Mrus and Robert Ryan and James Witek",
year = "2012",
month = "6",
day = "1",
doi = "10.1089/aid.2011.0118",
language = "English",
volume = "28",
pages = "544--551",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Efficacy and safety outcomes among treatment-experienced women and men treated with etravirine in gender, race and clinical experience

AU - Hodder, Sally

AU - Jayaweera, Dushyantha T

AU - Mrus, Joseph

AU - Ryan, Robert

AU - Witek, James

PY - 2012/6/1

Y1 - 2012/6/1

N2 - The GRACE (Gender, Race and Clinical Experience) trial enrolled treatment-experienced, HIV-1-infected patients, mainly women, in North America, to assess outcomes with a darunavir/ritonavir-based regimen, which could include etravirine (ETR). We present outcomes at week 48 for men and women receiving ETR. Virologic response (HIV-1 RNA <50 copies/ml) and safety were assessed; descriptive statistics are reported. To evaluate the independent contribution of ETR treatment, a post hoc analysis including a multivariate model assessed factors predictive of virologic response for the entire GRACE population (429 patients). Of 207 patients who received ETR (women, 57.5%; black or Hispanic, 81.7%), 71.4% of women and 79.5% of men completed the study. Week 48 virologic response rates in women and men (intent-to-treat population) were 58.0% and 61.4%, respectively. After censoring patients who discontinued treatment for reasons other than virologic failure, response rates were 79.3% and 73.0%, respectively. Overall, ETR was well tolerated. Women experienced more nausea (24.4% vs. 11.4%) and rash-related events (21.0% vs. 15.9%), but less diarrhea (15.1% vs. 21.6%), compared with men. Grade 3-4 hypertriglyceridemia was more common in men (9.3%) than women (1.1%). In total, 11 (9.2%) women and 7 (8.0%) men discontinued ETR due to adverse events. In the multivariate model of the entire GRACE population, ETR use was independently associated with improved virologic response. ETR is effective and well tolerated in treatment-experienced patients with HIV-1, with similar outcomes among women and men.

AB - The GRACE (Gender, Race and Clinical Experience) trial enrolled treatment-experienced, HIV-1-infected patients, mainly women, in North America, to assess outcomes with a darunavir/ritonavir-based regimen, which could include etravirine (ETR). We present outcomes at week 48 for men and women receiving ETR. Virologic response (HIV-1 RNA <50 copies/ml) and safety were assessed; descriptive statistics are reported. To evaluate the independent contribution of ETR treatment, a post hoc analysis including a multivariate model assessed factors predictive of virologic response for the entire GRACE population (429 patients). Of 207 patients who received ETR (women, 57.5%; black or Hispanic, 81.7%), 71.4% of women and 79.5% of men completed the study. Week 48 virologic response rates in women and men (intent-to-treat population) were 58.0% and 61.4%, respectively. After censoring patients who discontinued treatment for reasons other than virologic failure, response rates were 79.3% and 73.0%, respectively. Overall, ETR was well tolerated. Women experienced more nausea (24.4% vs. 11.4%) and rash-related events (21.0% vs. 15.9%), but less diarrhea (15.1% vs. 21.6%), compared with men. Grade 3-4 hypertriglyceridemia was more common in men (9.3%) than women (1.1%). In total, 11 (9.2%) women and 7 (8.0%) men discontinued ETR due to adverse events. In the multivariate model of the entire GRACE population, ETR use was independently associated with improved virologic response. ETR is effective and well tolerated in treatment-experienced patients with HIV-1, with similar outcomes among women and men.

UR - http://www.scopus.com/inward/record.url?scp=84861915880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861915880&partnerID=8YFLogxK

U2 - 10.1089/aid.2011.0118

DO - 10.1089/aid.2011.0118

M3 - Article

VL - 28

SP - 544

EP - 551

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 6

ER -